Dermatology Unit and Genodermatosis Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Piazza Sant'Onofrio 4, 00165, Rome, Italy.
Pediatric Dermatology, Hospital Sant Joan de Deu, Barcelona, Spain.
Eur J Med Genet. 2022 Jun;65(6):104517. doi: 10.1016/j.ejmg.2022.104517. Epub 2022 Apr 27.
The European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), is dedicated to gathering the best expertise in Europe and provide accessible cross-border healthcare to patients with rare vascular diseases. Infantile Hemangiomas (IH) are benign vascular tumors of infancy that rapidly growth in the first weeks of life, followed by stabilization and spontaneous regression. In rare cases the extent, the localization or the number of lesions may cause severe complications that need specific and careful management. Severe IH may be life-threatening due to airway obstruction, liver or cardiac failure or may harbor a risk of functional impairment, severe pain, and/or significant and permanent disfigurement. Rare IHs include syndromic variants associated with extracutaneous abnormalities (PHACE and LUMBAR syndromes), and large segmental hemangiomas. There are publications that focus on evidence-based medicine on propranolol treatment for IH and consensus statements on the management of rare infantile hemangiomas mostly focused on PHACES syndrome. The Vascular Anomalies Working Group (VASCA-WG) decided to develop a diagnostic and management pathway for severe and rare IHs with a Nominal Group Technique (NGT), a well-established, structured, multistep, facilitated group meeting technique used to generate consensus statements. The pathway was drawn following two face-to-face meetings and in multiple web meetings to facilitate discussion, and by mail to avoid the influence of most authoritative members. The VASCA-WG has produced this opinion statement reflecting strategies developed by experts and patient representatives on how to approach patients with severe and rare IH in a practical manner; we present an algorithmic view of the results of our work.
欧洲罕见多系统血管疾病参考网络(VASCERN)致力于汇集欧洲的最佳专业知识,并为罕见血管疾病患者提供可及的跨境医疗服务。婴儿血管瘤(IH)是婴儿期的良性血管肿瘤,在生命的最初几周内迅速生长,随后稳定并自发消退。在极少数情况下,病变的范围、位置或数量可能会导致严重的并发症,需要进行特定和仔细的管理。严重的 IH 可能因气道阻塞、肝或心力衰竭而危及生命,也可能存在功能障碍、严重疼痛和/或明显和永久性毁容的风险。罕见的 IH 包括与皮肤外异常相关的综合征变体(PHACE 和 LUMBAR 综合征)和大节段性血管瘤。有一些出版物专注于 IH 普萘洛尔治疗的循证医学和罕见婴儿血管瘤管理的共识声明,主要集中在 PHACES 综合征。血管异常工作组(VASCA-WG)决定使用名义团体技术(NGT)为严重和罕见 IH 制定诊断和管理途径,这是一种经过验证的、结构化的、多步骤的、有促进作用的团体会议技术,用于生成共识声明。该途径是在两次面对面会议和多次网络会议中制定的,以促进讨论,并通过邮件进行,以避免最权威成员的影响。VASCA-WG 提出了这一观点声明,反映了专家和患者代表制定的策略,以务实的方式为严重和罕见 IH 患者提供治疗方法;我们提出了我们工作成果的算法视图。